Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) is silenced by promoter methylation in many types of tumors, yet ASC's role in most cancers remains unknown. Here, we show that ASC is highly expressed in a model of medulloblastoma, the most common malignant pediatric brain cancer; ASC is also expressed in human medulloblastomas. Importantly, while ASC deficiency did not affect normal cerebellar development, ASC knockout mice on the Smoothened (ND2:SmoA1) transgenic model of medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed tumor onset. A similar decrease in tumorigenesis with ASC deficiency was also seen in the hGFAP-Cre:SmoM2 mouse model of medulloblastoma. Interestingly, hyperproliferation of the external granule layer (EGL) was comparable at P20 in both wild-type and ASC-deficient SmoA1 mice. However, while the apoptosis and differentiation markers remained unchanged at this age, proliferation makers were decreased, and the EGL was reduced in thickness and area by P60. This reduction in proliferation with ASC deficiency was also seen in isolated SmoA1 cerebellar granule precursor cells in vitro, indicating that the effect of ASC deletion on proliferation was cell autonomous. Interestingly, ASC-deficient SmoA1 cerebella exhibited disrupted expression of genes in the transforming growth factor-b pathway and increased level of nuclear Smad3. Taken together, these results demonstrate an unexpected role for ASC in Sonic hedgehog-driven medulloblastoma tumorigenesis, thus identifying ASC as a promising novel target for antitumor therapy.
INTRODUCTION
Medulloblastoma, a tumor of cerebellar progenitors, is the most common malignant brain cancer in children. 1 During normal development, proliferation of progenitors in the cerebellum extends into the early postnatal period, as cerebellar granule neuron progenitors (CGNPs) undergo rapid division in the external granule layer (EGL), and then differentiate and migrate to the internal granule layer (IGL). 2 CGNPs proliferate in response to endogenous Sonic hedgehog (Shh; mouse), and mutations that activate SHH (human) signaling cause predisposition to medulloblastoma in humans with Gorlin syndrome, and in genetically engineered mouse models. 1, 3 These models, which operate through either Patched deletion or insertion of constitutively active alleles of Smoothened (Smo), consistently implicate CGNPs as the cells of origin for Shh-driven medulloblastoma. 4, 5 Importantly, while advances in treatment have increased the survival of patients with medulloblastoma, mortality remains significantly high and debilitating cognitive and endocrine side effects result from current treatment regimens. 3 Thus, advancing the understanding of the genetic components of medulloblastoma tumorigenesis is needed to develop improved targeted therapies.
ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain; also known as TMS-1, target of methylationinduced silencing-1, and Pycard) is expressed in many human tissues; however, it is silenced by promoter hypermethylation in many tumor types, including glioblastoma, 6 neuroblastoma, 7 breast cancer, 8 melanoma 9 and lung cancer. 10 Ectopic ASC expression sensitizes pancreatic, breast and colon cancer cells to apoptosis, 8, [11] [12] [13] [14] [15] whereas knocking down endogenous ASC inhibits cell death of osteosarcoma cells, 13 colon cells 15 and breast epithelial cells. 16 In addition, ASC is the adaptor protein of the inflammasome, a cytosolic complex that senses pathogen-associated molecules and subsequently responds by activating proinflammatory substrates, prointerleukin-1b (pro-IL-1b) and pro-IL-18, which recruit and activate immune cells. [17] [18] [19] Consistent with the expectation that ASC inactivation promotes tumorigenesis, ASC deficiency has been shown to enhance polyp formation in a colitis-associated colon cancer mouse model. 20, 21 Taken together, these studies point to ASC as a functional tumor suppressor.
In this study, we examined the role of ASC in medulloblastoma using mouse models. Our results reveal the unexpected finding that ASC promotes tumorigenesis in medulloblastoma. ASC was highly expressed in these tumors and the genetic deletion of ASC markedly reduced proliferation, hyperplasia and mortality. These findings identify a novel role for ASC in promoting tumorigenesis in medulloblastoma.
RESULTS AND DISCUSSION
ASC is highly expressed in medulloblastomas To investigate the role of ASC in cerebellar development and medulloblastoma, we evaluated ASC expression during mouse Figure 1 . ASC is expressed in the cerebellum and medulloblastoma but ASC deficiency does not affect normal cerebellum development. (A) Western blot analysis of cerebellar lysates reveals ASC expression during normal cerebellum development and increased ASC expression in medulloblastoma. (Tumor sample shown is from postnatal 101-day-old, P101, mouse.) Densitometric quantification reveals that ASC levels are increased in medulloblastomas. Data are mean of four separate experiments ± s.e.m. analyzed by Student's t-test (P ¼ 0.014, 0.019) and one-way analysis of variance (ANOVA) (P ¼ 0.029); n ¼ 3-4 per group. ASC levels are normalized to loading controls and average P60 levels were set to 1.0 for each experiment. *Po0.05. Cerebella were collected at specified ages and lysates were probed with antibodies against ASC (Alexis Biochemicals, Lausen, Switzerland; Adipogen, San Diego, CA, USA), cyclin D2 (CD2; Cell Signaling, Danvers, MA, USA) and a-tubulin (Sigma-Aldrich, St Louis, MO, USA). (B) Quantitative real-time polymerase chain reaction (qRT-PCR) analysis demonstrates ASC mRNA decreases during normal cerebellum development and is induced in medulloblastoma. Cerebella were collected at the ages specified (n ¼ 4-6 per age). Tumors were collected at an average age of P138 (P101-P205; n ¼ 8). qRT-PCR was conducted similarly as described previously, 45 using primers Pycard-FW (5 0 -GACCAGCACAGGCAAGCA-3 0 ), Pycard-Rev (5 0 -TCCAGCACTCCGTCCACTTC-3 0 ), Gapdh-FW (5 0 -TGTGTCCGTCGTGGATCTGA-3 0 ) and Gapdh-Rev (5 0 -CCTGCTTCACCACCTTCTTGA-3 0 ) and normalizing to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels. Data are mean±s.e.m. analyzed by the Mann-Whitney test. Experiments were carried out in triplicate four times. **Po0.01; *Po0.05. (C) RNA in situ hybridization (ISH) of human medulloblastoma tissue microarray sections for (a) DapB (negative control), (b) PPIB (positive control) and four representative samples where ASC expression was scored as (c) 0 (no signal), (d) 1 (rare signal), (e) 2 (scattered signal) or (f) 3 (ubiquitous signal). RNA ISH was performed and ASC expression was quantified as described in Table 1 . The scatter plot shows mean ASC expression score and s.e.m. for classic and desmoplastic tumors. The average score was 1.3 for classic tumors (n ¼ 11), 2.3 for desmoplastic tumors (n ¼ 3) and 2.0 for large-cell/anaplastic medulloblastoma (n ¼ 1). The difference between the desmoplastic and classic groups was not significant (P ¼ 0.12; Student's t-test). No correlation between ASC score and age or gender was observed. Scale bar represents 10 mm. (D) Oncomine analysis of independent gene profiling studies, with data from Kool et al. 22 and Fattet et al. 23 was used to compare ASC mRNA expression levels in classic versus desmoplastic human primary medulloblastomas. Each data set had equivalent proportions of desmoplastic tumors (22%) and classic tumors (78%) and F-test analysis determined the data sets did not have unequal variance (F ¼ 0.054). Data are medians with 95% confidence intervals for ASC mRNA in the combined data sets (*P ¼ 0.047, two-tailed t-test; n ¼ 74 classic; n ¼ 21 desmoplastic). Correction for potential technical bias between data sets, by adjusting values to make each data set mean equal zero, yielded similar results (P ¼ 0.025; data not shown). (E) Representative images of hematoxylin and eosin (H&E)-stained sagittal sections of ASC þ / þ and ASC À / À cerebella at specified ages show no differences in gross cerebellar architecture with development between genotypes (n ¼ 3-8 per group). Scale bars represent 1 mm and 200 mm (inset). (F) ASC þ / þ and ASC À / À cerebellar lysates at specified ages were immunoblotted as described above. (G) Immunohistochemistry (IHC) for pH3 (Cell Signaling) in P7 ASC þ / þ and ASC À / À sagittal cerebellar sections. Quantitative comparison of cells expressing pH3 in ASC þ / þ and ASC À / À EGL (n ¼ 3-7 per group). The EGL region was manually annotated using Aperio ImageScope V12 and analyzed with Aperio Nuclear V9 Algorithm (Aperio Technologies Inc., Vista, CA, USA). The data represent mean ± s.e.m. analyzed by Student's t-test. Scale bar represents 200 mm. cerebellum development. ASC protein levels were high in postnatal day 7 (P7) cerebellum, which corresponds to the peak period of CGNP cell proliferation, and decreased with cerebellar maturation (Figure 1a ). ASC is reported to enhance apoptosis upon expression and is often silenced via methylation in a variety of cancers. 8, [11] [12] [13] [14] To determine whether ASC was also silenced in cancer of cerebellar origin, we examined ASC expression in medulloblastoma. We used the ND2:SmoA1 (SmoA1) mouse model of medulloblastoma, which expresses an activated allele of Smo in CGNPs, resulting in CGNP hyperproliferation and tumor growth as a consequence of the constitutive activation of the Shh pathway. 5 In contrast to the reports in other cancer types, we unexpectedly detected high levels of ASC in medulloblastoma ( Figure 1a ). Also, ASC mRNA levels closely matched protein levels throughout development and in the tumor (Figure 1b ). These data reveal the surprising observation that ASC is not subjected to silencing but is induced in a mouse model of medulloblastoma.
To investigate ASC expression in human medulloblastomas, we conducted in situ hybridization (ISH) on sections of a tissue microarray from 11 classic, 3 desmoplastic and 1 large-cell/ anaplastic medulloblastomas obtained from 15 patients (8 males and 7 females; ages 1-38, median age ¼ 15 years). Overall, the majority (60%) were positive for ASC, including 45.5% of classic tumors, 100% of desmoplastic tumors and the large-cell/ anaplastic tumor (Table 1) . Classic tumors exhibited a range of ASC expression, whereas all desmoplastic tumors were positive for ASC expression ( Figure 1c ). Examination of publicly available gene expression profiling data in the Oncomine database also reveals ASC to be expressed in human medulloblastomas, with significantly increased expression in desmoplastic versus classic tumors ( Figure 1d ). 22, 23 Furthermore, a recent paper reported ASC amplification to be a frequent genetic event in the human medulloblastomas studied. 24 Taken together, these data indicate that ASC is expressed in a significant portion of human medulloblastomas.
ASC deficiency does not affect normal cerebellum development
To investigate whether ASC expression is important in medulloblastoma tumorigenesis, we first evaluated whether ASC deficiency affected normal cerebellar development. Cerebellar development occurs postnatally with rapid CGNP proliferation in the EGL peaking at P7. As CGNPs terminally differentiate into CGNs, they migrate to the IGL to form the mature cerebellum by P20. 2 We therefore compared cerebellar architecture of ASC þ / þ and ASC À / À mice during this key developmental period. Hematoxylin and eosin staining revealed no differences in gross morphology between wild-type and ASC-deficient cerebella throughout development (Figure 1e ). To specifically examine whether proliferation was altered by ASC deficiency, we compared expression of proliferation markers cyclin D2 and phospho-histone H3 (pH3) in ASC þ / þ and ASC À / À P7 cerebellum. No differences in cyclin D2 levels and pH3 staining were observed between wildtype and ASC-deficient cerebella (Figures 1f and g) .
ASC deficiency suppresses SmoA1-and SmoM2-induced medulloblastoma
Next, to determine whether ASC deficiency affects medulloblastoma, we generated ASC þ / þ , ASC þ / À and ASC À / À SmoA1 mice and compared the time of tumor emergence in each group. In this Smo transgenic medulloblastoma model, signs of tumors typically emerge at 3-8 months and precede death from the disease by only a few days; thus, once signs emerge, mice are in a moribund state. 5 Surprisingly, ASC deficiency conferred a striking reduction in tumor incidence and delay in tumor onset in the transgenic mice (Figure 2a ). Overall tumor incidence by P300 was significantly reduced in mice lacking ASC: (Figure 2a ). ASC heterozygous mice also exhibited a delayed rate of tumorigenesis when compared with wild-type mice (Figure 2a ). To test whether ASC deficiency affects tumorigenesis in another model of medulloblastoma, we utilized the SmoM2 model. SmoM2 is a constitutively active Shh-driving Smo mutation discovered to induce aggressively medulloblastoma in mice by P20. [25] [26] [27] We generated ASC þ / þ , ASC þ / À and ASC À / À hGFAP-Cre:SmoM2 (SmoM2) mice and evaluated time to tumor emergence and moribund status. ASC deficiency markedly reduced tumorigenesis in the SmoM2 model, with loss of even one ASC allele extending survival (Figure 2c ). Although all mice developed medulloblastoma in this model, the average age at which mice became moribund was delayed in ASC heterozygous and knockout mice (Figure 2d ). Thus, ASC deficiency profoundly reduced tumorigenesis and extended survival in two distinct mouse models of medulloblastoma.
One of the known functions of ASC is that it is an adaptor protein for the inflammasome, a complex that, when triggered by intracellular signals, cleaves proinflammatory substrate pro-IL-1b into its active form. [17] [18] [19] IL-1b has been reported to have several functions promoting cancer, 28 although it has not been studied in medulloblastoma. To determine whether IL-1b is required for medulloblastoma development, we evaluated tumorigenesis in IL-1b-deficient mice in the SmoA1 model. In contrast to our results with the loss of ASC, IL-1b deficiency did not affect medulloblastoma onset or incidence ( Supplementary Figure 1) . To determine the point at which ASC deficiency blocks tumorigenesis in medulloblastoma, we compared wild-type and ASC-deficient SmoA1 cerebella at multiple time points during tumor development. In this tumor model, ectopic CGNP proliferation can be detected by P20 and progresses into tumor in adulthood. To examine whether ASC deficiency affects CGNP hyperproliferation during the pretumor stages (P20, P60), histological hematoxylinand eosin-stained sections of ASC þ / þ and ASC À / À SmoA1 cerebella were compared. ASC À / À ;SmoA1 cerebella exhibited equivalent ectopic CGNP proliferation and EGL architecture as seen in ASC þ / þ ;SmoA1 mice at P7 and P20. However, by P60, ASC deletion significantly reduced the proportion and thickness of EGL in the cerebella (Figures 3a-c) . Thus, ASC deficiency did not block the initial stages of CGNP hyperproliferation, but markedly diminished ectopic EGL in the cerebellum by P60.
ASC-deficient SmoA1 cerebella exhibit reduced proliferation
Tumorigenesis can be regulated by the balance of proliferation, differentiation and apoptosis. We sought to determine which factors were responsible for the requirement of ASC in Shh-driven medulloblastoma. To test whether proliferation was altered in the ASC knockout cerebella in the SmoA1 medulloblastoma model, we performed western blot analysis for cyclin D2 and immunohistochemistry for the mitotic marker pH3 in wild-type and ASCdeficient SmoA1 mice. Cyclin D2 levels were unchanged at P7, but were strikingly reduced by P60, at which point cyclin D2 levels were virtually undetectable in the ASC-deficient mice but were sustained in the wild-type mice on the SmoA1 background (Figure 3d ). Thus, even though gross reduction in hyperplasia was not detected by P20 in the ASC À / À ;SmoA1 cerebella, markers of proliferation showed an emerging trend of reduction at this time point. To test directly whether ASC expression affected proliferation of the CGNPs in the EGL, we conducted pH3 immunohistochemistry. Consistent with the reduction in cyclin D2 levels, pH3 staining was reduced by nearly 50% at P20, revealing a lower mitotic frequency in the EGL with ASC deletion (Figures 3e and f) . These results identify a role for ASC in regulating ectopic proliferation of CGNPs in medulloblastoma in vivo.
We next examined whether the effect of ASC on proliferation of CGNPs in this tumor model was cell autonomous. CGNPs from ASC þ / À ;SmoA1 and ASC À / À ;SmoA1 mice were isolated and maintained for 2 days in vitro. Western blot analysis revealed that ASC deficiency reduced the proliferation marker cyclin D2 even in these isolated tumor cells ( Figure 3g ). These data suggest a cell intrinsic effect of ASC on CGNP proliferation in the SmoA1 model. However, we cannot exclude the possibility that ASC deficiency could also affect stromal signals to modulate CGNP proliferation in vivo.
Previous studies have reported a decrease in proliferation with ASC deficiency in stimulated CD4 þ and CD8 þ T cells, splenocytes and lymph node cells. [29] [30] [31] However, other studies have reported either no difference in proliferation of ASC knockout splenocytes or an increase in proliferation with ASC deletion in keratinocytes. 32, 33 Taken together, these data point to a complex role for ASC in regulating cell proliferation, with our results showing that ASC deficiency markedly reduces proliferation in medulloblastoma.
Numerous studies have shown that ASC is proapoptotic when overexpressed in cancer cell lines. 8, [11] [12] [13] [14] [15] Furthermore, knockdown of endogenous ASC reduces apoptosis of breast epithelial cells, 16 colon cancer cells 15 and osteosarcoma cells. 13 We examined whether ASC altered apoptosis or differentiation during tumorigenesis and found no statistical differences in the differentiation marker NeuN or the apoptosis marker cleaved caspase-3 between wild-type and ASC-deficient P20 SmoA1 EGL (Figures 3e and f) . Likewise, other groups have found no difference in apoptosis with loss of endogenous ASC in keratinocytes or splenocytes. 31, 33 Taken together, these results identify reduced proliferation as the likely key factor suppressing medulloblastoma tumorigenesis in ASCdeficient mice.
ASC-deficient SmoA1 cerebella exhibit altered TGF-b pathway gene expression and increased nuclear Smad3
To determine the mechanism by which ASC deficiency inhibits proliferation in medulloblastoma, we conducted a microarray analysis comparing gene expression of ASC À / À versus ASC þ / þ cerebella on the SmoA1 background. We focused on P20 because the differences in the ASC À / À and ASC þ / þ cerebellar phenotypes begin to emerge at this timepoint. Microarray data are available in Gene Expression Omnibus under the accession number GSE48682. Microarray analysis revealed only three genes (in addition to ASC) to be differentially expressed between ASC À / À and ASC þ / þ SmoA1 cerebella at this timepoint ( Table 2 ). The fact that only a small number of genes were identified to be differentially expressed is not surprising as differences in the tumor phenotype are just emerging at the P20 timepoint. Of the three differentially expressed genes identified, Tgfb1i1 (transforming growth factor beta-1-induced transcript 1), which was 2.5-fold higher in the ASC knockout samples, is known to be upregulated with TGF-b (transforming growth factor-b). 34 Interestingly, Tgfb1i1 (also known as Hic-5) has been reported to inhibit cell proliferation when overexpressed in cells. 35, 36 We next examined whether the TGF-b pathway was altered in the absence of ASC. Indeed, quantitative polymerase chain reaction (PCR) analysis confirmed dysregulation of TGF-b pathway genes in the knockout mice, with Tgfb1i1 significantly upregulated, while the TGF-b inhibitor Tgif1 was significantly downregulated in ASC-deficient P20 SmoA1 mice. Furthermore, cell cycle genes cyclin D2 and Cdk2 were decreased in the ASC knockout SmoA1 cerebella (Figure 4a ). Technologies) . For all, 1000 ng RNA from pooled P16 wild-type cerebella was amplified and labeled with Cy3 as a reference for each sample. Raw data was processed and analyzed by GeneSpring GX Version 11.0 (Agilent Technologies). Genes with a corrected P-value o0.05 following unpaired t-test and Benjamini and Hochberg false discovery rate procedure were considered differentially expressed. Dysregulation of the TGF-b pathway has been recognized in a subgroup of medulloblastomas. [37] [38] [39] To investigate whether TGF-b signaling is altered in ASC À / À transgenic cerebella, we evaluated cellular phospho-Smad3 localization using immunohistochemistry. Interestingly, we found a greater percentage of cells with nuclear Smad3 in the ASC-deficient transgenic cerebella (Figure 4b) . These data reveal an unexpected link between ASC and the TGF-b pathway whereby ASC-deficient cerebella exhibit altered TGF-b pathway gene expression and increased nuclear Smad3 in a mouse model of medulloblastoma.
Interestingly, TGF-b activation has a dual role in cancer, as the pathway promotes epithelial-mesenchymal transition and metastasis, but early TGF-b activation restricts tumorigenesis by inducing apoptosis and reducing cell proliferation. 40, 41 The dichotomous effects of the TGF-b pathway are evident in medulloblastoma. One group found disruption of TGF-b pathway genes in one of four subsets of medulloblastoma, namely deletion of TGF-b inhibitors and amplification of Type II activin receptors and TGFBR1. 37 In contrast, we observed an association between increased TGF-b pathway gene expression and signaling and decreased CGNP proliferation in the ASC knockout SmoA1 P20 cerebella. Consistent with our results, increasing TGF-b signaling with BMP2/4 addition or Smad5 overexpression in the presence of Shh stimulation reduces CGNP proliferation. 42, 43 Furthermore, increased nuclear Smad3 in SHH-related human medulloblastomas is correlated with a more favorable prognosis. 38 Although these results in medulloblastoma identify a clear role of ASC in promoting tumorigenesis, ASC has also been described as a tumor suppressor in specific cancer models. ASC suppresses tumorigenesis in a colitis-associated colon cancer mouse model, where ASC deficiency enhanced polyp formation and clinical exacerbation, resulting in reduced survival. 20, 21 In a model of squamous cell carcinoma, selective deletion of ASC in bone marrow-derived macrophages suppressed tumor number but ASC ablation in keratinocytes promoted tumorigenesis. 33 When ASC was deleted from the whole animal, ASC knockout mice showed no differences from wild-type in tumor susceptibility. 33 In melanoma, a recent study found that ASC-deficient metastatic melanoma cells injected into nude mice displayed reduced tumor growth as compared with wild-type tumor cell implantation. In contrast, ASC-deficient primary melanoma implants hastened tumor growth versus wild-type controls. 44 Thus, the role of ASC in carcinogenesis appears to depend on the cancer, cell type and stage of cancer progression.
In summary, our results identify a critical function of ASC in driving proliferation and tumorigenesis in Shh pathway-driven models of medulloblastoma. Improved therapeutics for this cancer are needed because of the high mortality and devastating side effects of current treatment. Our results show that targeting ASC may be a promising strategy for preventing tumor progression of medulloblastoma.
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